Affiliation:
1. Russian Medical Academy of Continuing Postgraduate Education, Federal State Budgetary Educational Institution of Further Professional Education of the Ministry of Health of Russia
Abstract
COPD exacerbations occur in almost all patients, and half of patients in the Russian Federation (52%) have two or more exacerbations per year or require urgent admission to hospital. COPD exacerbations come from increased acute inflammation in the respiratory tract of a patient under the influence of many factors. Modern pharmacotherapy provides the physician with several options in reducing the number of exacerbations. This review provides evidence about the maximum reduction in exacerbation risk due to the administration of tiotropium/olodaterol combination or triple therapy.
Reference95 articles.
1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available from: https://goldcopd.org.2017.
2. Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3255-3262.
3. Jones PW, Lamarca R, Chuecos F et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J, 2014, 44: 1156-1165.
4. Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med, 2017, 128: 85-91.
5. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. Suppl, 2003, 41: 46-53.